Anesthetic Management of Pediatric Pulmonary Arterial Hypertension

Yıl 2015, Cilt: 24 Sayı: 2, 149 - 158, 05.03.2015

Mediha Türktan Zehra Hatipoğlu

https://doi.org/10.17827/aktd.05308

Öz

Pulmonary arterial hypertension is the most important cause of morbidity and mortality associated with congenital heart disease. Patients in this group have a greater peroperative cardiovascular risks including cardiac arrest, pulmonary hypertensive crisis and death compared the normal population. The main purpose of anesthesia is to avoid increased pulmonary vascular resistance and myocardial depression.

Anahtar Kelimeler

Pulmonary arterial hypertension, congenital heart disease, anesthesia

Pediyatrik Pulmoner Arteriyal Hipertansiyonda Anestezik Yaklaşım

Öz

Pulmoner arteriyal hipertansiyon konjenital kalp hastalıklarına bağlı morbidite ve mortalitenin en
önemli nedenidir. Bu gruptaki hastalar normal popülasyonla karşılaştırıldığında kardiyak arrest,
pulmoner hipertansif kriz ve ölümü de içeren peroperatif kardiyovasküler komplikasyonlara daha fazla
sahiptir. Anestezide temel amaç, pulmoner vasküler direnç artışı ve myokard depresyonundan
kaçınmaktır

Anahtar Kelimeler

Pulmoner arteriyal hipertansiyon, konjenital kalp hastalıkları, anestezi

Kaynakça

• Friesen RH, Williams GD. Anesthetic Management of Children with Pulmonary Arterial Hypertension. Paediatr Anaesth. 2008;18:208-16.
• Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5–12.
• Kanbay A, Büyükoğlan H, Oymak FS, Demir R. Pulmoner hipertansiyon ve yeni sınıflama. Yeni Tıp Dergisi. 2010;27:208-12.
• Tuncel Z, Kuddisioğlu ŞT, Aykaç Z. Pediyatrik konjenital kalp hastalıklarına bağlı pulmoner hipertansiyonda anestezik yaklaşım. GKDA Dergisi. 2013;19:2-9.
• Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth. 2007;98:657–61. 6. Carmosino MJ, Friesen RH, Doran A, Ivy DD. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg. 2007;104:521-7.
• Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery. J Am Coll Cardiol. 2005;45:1691-9.
• Friesen RH, Alswang M. Changes in carbon dioxide tension and oxygen saturation during deep sedation for paediatric cardiac catheterization. Pediatr Anesth. 1996;6:15-20.
• Williams GD, Maan H, Ramamoorthy C, Kamra K, Bratton SL, Bair E, et al. Perioperative complications in children with pulmonary hypertension undergoing general anesthesia with ketamine. Pediatric Anesthesia. 2010;20: 28–37.
• Abman SH. Neonatal pulmonary hypertension: a physiologic approach to treatment. Pediatr Pulmonol Suppl. 2004;26:127-8.
• Foubert L, Fleming B, Jonas M, Oduro A, Borland C, Higenbottam T. Safety guidelines for use of nitric oxide. Lancet. 1992;339:1615-6.
• Bizzarro M, Gross I, Barbosa FT. Inhaled nitric oxide for the postoperative management of pulmonary hypertension and children with congenital heart disease. Cochrane Database Syst Rev. 2014 Jul 3;7:CD005055.2009;4.
• Palma G, Giordano R, Russolillo V, Cioffi S, Palumbo S, Mucerino M, et al. Sildenafil theraphy for pulmonary hypertension before and after pediatric cardiac surgery. Tex Heart Inst J. 2011;38:238- 42.
• De Wolf D. Clinical practice: pulmonary hypertension in children. Eur J Pediatr. 2009;168:515-22.
• McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A.Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med. 2013;14:74-84.
• Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol. 1995;48: 890–896.
• Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197–208.
• Maiya S, Hislop AA. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92: 664-70.
• Yung D, Widlitz A, Rosenzweig E, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004;110:660–5.
• Gottlieb J. Update on lung transplantation. Ther Adv Respir Dis. 2008;2:237-47.
• Correspondence Address / Yazışma Adresi